Unlocking the Future of Drug Development with Mystra
Mystra, a groundbreaking platform created by Genomics over a decade, presents biopharma organizations with unmatched analytical capabilities that significantly shorten research and development timelines. By converting months of labor into a matter of minutes, Mystra enhances the likelihood of identifying effective drug candidates through superior genetic insights.
The Challenge in the Pharmaceutical Landscape
The pharmaceutical industry is grappling with a dire productivity crisis, as the failure rate for drug candidates in clinical trials reaches an alarming 95%. This staggering statistic drives the average expenditure to launch a new medication beyond $2.3 billion, creating unaffordable pricing and hampering access to essential treatments for patients. Genomics seeks to mitigate this issue by providing researchers with advanced solutions that tap into the genetic foundations of drug development.
The Role of Human Genetics in Success
Research shows that drug targets bolstered by human genetic evidence enjoy a 2.6 times greater success rate in clinical trials. Acknowledging this fact, Genomics has devoted years to compiling and refining the world's most extensive human genotype-phenotype database. Mystra leverages these insights to facilitate drug development while deepening the understanding of disease mechanisms through genetic variation studies.
Advanced Technology Meets Drug Discovery
Mystra utilizes leading-edge algorithms to provide clear insights supported by substantial evidence from genetic studies. It enhances the research process by accelerating data analyses that were traditionally turned around only after extended periods. Currently, genetics teams face challenges managing disparate datasets and executing manual analytics. The time-consuming process often delays valuable insights that could inform discovery strategies. Mystra aims to integrate tools and data, significantly expediting collaboration across varied scientific teams.
The Transformative Advantages of Mystra
Mystra redefines how human genetics can drive drug discovery and clinical development. By synthesizing genomic resources, analytical tools, and collaboration avenues onto a single platform, it bolsters productivity for genetics teams. With improved insights, researchers can confirm drug target validity, efficiently design clinical trials, and navigate decision-making processes all while collaborating seamlessly.
Key Features of the Mystra Platform
Mystra represents the culmination of years of tireless work, delivering a secure and intuitive platform tailored for user engagement. Key functionalities include:
- Build Genetic Conviction: Quickly evaluate the safety and efficacy of drug candidates against a rich repository of genetic evidence.
- Accelerate R&D: Transform intricate genetic analysis processes that previously took months into instantaneous outcomes.
- De-Risk Investment: Enhance the success rates of drug candidates by selecting the most promising options for the pipeline.
As emphasized by Dave Thornton, President of Genomics, their decade-long endeavor in building a comprehensive genetic insights platform empowers biopharma partners. "Today, we are making this advanced technology available to R&D scientists, facilitating real-time, data-driven decisions that redefine drug development trajectories. This allows us to deliver effective treatments to patients sooner and with improved safety."
Accessible Solutions for Pharma and Biotech
Mystra is the first solution to offer scalable options for life sciences entities that harness multi-omic data for research and development. Given the complexity of omics data, expert knowledge and sophisticated methods are required to distill actionable insights. Genomics offers flexible engagement strategies for pharmaceutical and biotech partners to utilize Mystra's expansive capabilities.
Selecting the Right Engagement Model
Pharmaceutical companies are capable of leveraging Mystra through various models:
- Self-service (SaaS): Teams gain direct access to the platform’s datasets and tools.
- Partly Managed: Internal data is integrated with Genomics' datasets for custom analyses.
- Fully Managed: Collaborate with a proficient team of over 60 statistical genetic scientists to amplify research efforts.
Currently, major pharmaceutical organizations are trialing Mystra through an early-access initiative, with ongoing expansion of its capabilities to enhance the drug discovery process across scientific teams.
About Genomics
Genomics is a forward-thinking techbio organization harnessing extensive genetic data to innovate precision healthcare solutions. Established by a group of prominent geneticists from the University of Oxford, the company has been instrumental in revolutionizing pharmaceutical partnerships to predict, prevent, and treat various health conditions, effectively reducing the societal burden of prevalent diseases such as cancer and heart disorders.
Frequently Asked Questions
What is Mystra?
Mystra is the first AI-enabled human genetics platform designed to enhance drug target discovery and clinical development.
How does Mystra improve drug development?
The platform accelerates the identification of drug candidates by converting lengthy research processes into rapid analyses, ultimately increasing the chances of success.
Who developed Mystra?
Mystra was developed by Genomics, a science-led techbio company dedicated to advancing precision healthcare.
What are the engagement options for using Mystra?
Users can access Mystra through self-service, partly managed, or fully managed models depending on their needs.
What is the significance of human genetics in drug discovery?
Human genetics plays a vital role as drug targets supported by genetic evidence have a significantly higher success rate in clinical trials.
